News & Views | Published:


The role of ifosfamide and etoposide in Ewing sarcoma

Nature Reviews Clinical Oncology volume 6, pages 251253 (2009) | Download Citation

The EICESS-92 trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma. Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J. Clin. Oncol. 26, 4385–4393 (2008).

  2. 2.

    et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother. Pharmacol. 18, S25–S28 (1986).

  3. 3.

    et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. 5, 1191–1198 (1987).

  4. 4.

    et al. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J. Clin. Oncol. 10, 1407–1412 (1992).

  5. 5.

    et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J. Clin. Oncol. 16, 3628–3633 (1998).

  6. 6.

    et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J. Clin. Oncol. 19, 1818–1829 (2001).

  7. 7.

    et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694–701 (2003).

Download references

Author information


  1. University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA.

    • Steven G. DuBois
  2. Harvard Medical School, Boston, MA, USA.

    • Holcombe E. Grier


  1. Search for Steven G. DuBois in:

  2. Search for Holcombe E. Grier in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Holcombe E. Grier.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing